Trastuzumab and chemotherapy may be appropriate for small, node-negative, HER2-positive breast cancer

Oncologist. 2012;17(10):e33; author reply e34. doi: 10.1634/theoncologist.2012-0318.

Abstract

This letter discusses the outcomes of a sequential cohort study of women with T1, N0, HER2-positive breast cancer with trastuzumab.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology*
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Lymph Nodes / pathology
  • Lymphatic Metastasis
  • Receptor, ErbB-2 / biosynthesis*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab